Bexarotene has been approved for the treatment of cancer by the U.S. Food and Drug Administration for more than a decade. These experiments explored whether the medication might also be used to help patients with Alzheimer's disease, and the results were more than promising.
In particular, the researchers were struck by the speed with which bexarotene improved memory deficits and behavior even as it also acted to reverse the pathology of Alzheimer's disease. The present view of the scientific community is that small soluble forms of amyloid beta cause the memory impairments seen in animal models and humans with the disease. Within six hours of administering bexarotene, however, soluble amyloid levels fell by 25 percent; even more impressive, the effect lasted as long as three days. Finally, this shift was correlated with rapid improvement in a broad range of behaviors in three different mouse models of Alzheimer's.
When Bug got home from school one winter afternoon in late 2024, his mother was on...
More than 3.1 million bottles of eye drops sold at major retailers, including Walgreens and CVS,...
Donald Trump has selected Erica Schwartz to lead the Centers for Disease Control and Prevention (CDC),...
The Supreme Court sided with a Christian counselor on Tuesday in her free speech challenge to...
